Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Related Research units
Abstract
Bibliographical data
Original language | English |
---|---|
Article number | 2 |
ISSN | 0732-183X |
Publication status | Published - 2011 |
pubmed | 21115860 |
---|